JHL Biotech Reports Randomization of Patients in P-III Study of JHL1101 for Diffuse Large B-Cell Lymphoma

 JHL Biotech Reports Randomization of Patients in P-III Study of JHL1101 for Diffuse Large B-Cell Lymphoma

JHL Biotech Reports Randomization of Patients in P-III Study of JHL1101 for Diffuse Large B-Cell Lymphoma

Shots:
 
  • The study involves assessing of JHL1101 + CHOP (J-CHOP) vs rituximab + CHOP (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
  •  Post P-III Study of JHL1101 and combination therapy, JHL Biotech plans to conduct PK study in RA patients in EU
  • JHL1101 (biosimilar to Rituximab) is a mAb targeting CD20 cells, for non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and rheumatoid arthritis (RA)

Click here to read full press release/ article | Ref: PRNewswire   | Image: Asian Scientist Magazine

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post